Search hospitals > Maryland > Columbia

Maryland Oncology Hematology, PA

Claim this profile
Columbia, Maryland 21044
Global Leader in Breast Cancer
Global Leader in Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Cancer
Conducts research for Prostate Cancer
69 reported clinical trials
5 medical researchers
Photo of Maryland Oncology Hematology, PA in ColumbiaPhoto of Maryland Oncology Hematology, PA in ColumbiaPhoto of Maryland Oncology Hematology, PA in Columbia

Summary

Maryland Oncology Hematology, PA is a medical facility located in Columbia, Maryland. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Cancer, Prostate Cancer and other specialties. Maryland Oncology Hematology, PA is involved with conducting 69 clinical trials across 106 conditions. There are 5 research doctors associated with this hospital, such as Kashif Ali, Mohit Narang, MD, Yousuf Gaffar, MD, and Cheryl A Aylesworth.

Area of expertise

1Breast Cancer
Global Leader
Maryland Oncology Hematology, PA has run 20 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
Stage III
2Non-Small Cell Lung Cancer
Global Leader
Maryland Oncology Hematology, PA has run 16 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Stage IV
RET
Stage III

Top PIs

Clinical Trials running at Maryland Oncology Hematology, PA

Breast Cancer
Multiple Myeloma
Colorectal Cancer
Melanoma
Colon Cancer
Myelodysplastic Syndrome
Myelodysplastic/Myeloproliferative Neoplasms
Cytokine Release Syndrome
Rectal Cancer
Prostate Cancer
Image of trial facility.

Elacestrant

for Breast Cancer

The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Recruiting2 awards Phase 33 criteria
Image of trial facility.

Tucatinib + Doxil

for Breast Cancer

This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil
Recruiting1 award Phase 213 criteria
Image of trial facility.

Genomic Testing

for Breast Cancer

The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Recruiting1 award N/A3 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Maryland Oncology Hematology, PA?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security